Noisy
← this week  ·  Subscribe →

The world is being quietly rearranged by people who write very long documents.

Federal Register · June 26, 2025
The title they went with Medical Devices; Hematology and Pathology Devices; Classification of the Fluorescence In Situ Hybridization-Based Detection of Chromosomal Abnormalities From Patients With Hematologic Malignancies Noisy translates that to

US health regulators make it easier to approve new cancer diagnostic tests

What happened
US health regulators just moved a specific type of cancer diagnostic test into a lower risk category. This means companies can bring new versions of these tests to market faster and with less regulatory burden.
Why it matters
For years, new medical devices faced a long, expensive approval process, even for variations of existing technologies. This change means that a specific class of diagnostic tests, which use a common method to detect genetic changes in blood cancers, will now have a faster path to market. It should make it easier for doctors to access new tests as they become available.
The signal
Watch for an increase in the number of new fluorescence in situ hybridization-based tests for blood cancers appearing on the market in the next 12-24 months.
If you insist
Read the original →